Straits Times Index
3,305.81 +13.12 (+0.40%) Nikkei
38,299.71 +25.66 (+0.07%) Hang Seng
18,168.21 +405.18 (+2.28%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,497.78 -2,511.22 (-4.18%) CMC Crypto 200
1,261.06 -78.00 (-5.83%)
Cardiff Oncology Inc (XE7C.SG)
| Previous close | 1.0550 |
| Open | 1.0850 |
| Bid | 1.0700 x 0 |
| Ask | 1.1100 x 0 |
| Day's range | 1.0400 - 1.0850 |
| 52-week range | 0.8770 - 5.5000 |
| Volume | |
| Avg. volume | 27 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireCardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading. Conference Call and Webcast Cardiff Oncology will host
- GlobeNewswire
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutate
- GlobeNewswire
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced publications of five abstracts that will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5-10, 2024, in San Diego, California. “The posters we will be presenting at this year’s AACR meeting represent
